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Introduction
Brachytherapy has been revolutionised by modern
imaging technology, computer dosimetry, and high dose
rate (HDR) delivery systems. It is now possible to image
the gross tumour, define a clinical target volume, and
deliver radiation to this volume in a highly conformal
manner.
Difficulty arises, however, when brachytherapy is
delivered after the tumour has been excised. Typically,
afterloading catheters are placed in the tumour bed, and
the patient is imaged after the surgical wound is closed.
As there is no longer a gross tumour volume (GTV),
definition of a clinical target volume (CTV) is highly
subjective. We sought a more objective method of
prescription when high dose rate brachytherapy is utilised
for this situation.
Case report
A 69 year-old man related an eight month history of
a slowly growing subcutaneous mass on the medial aspect
of his right upper arm. Biopsy was consistent with
malignant high grade sarcoma. Magnetic resonance
imaging (MRI) of the extremity demonstrated an
enhancing soft tissue mass between the biceps and the
triceps muscles, adjacent to the neurovascular bundle;
its dimensions were 6.5 x 3.5 x 7.8 cm3. Staging studies
were negative for distant disease.
The patient underwent wide local excision of the
mass in September 2005. Catheters were placed across
the tumour bed (Figure 1a), and the wound closed with
a myocutaneous flap (Figure 1b). Surgical pathology
confirmed the tumour to be a 5.5 x 4.5 x 3.1 cm3
malignant fibrous histiocytoma. Although all margins
were negative, the deep margin, which was contiguous
with the neurovascular bundle, was less than 1 mm.
HDR dosimetry was calculated so that a dose of 450
cGy per fraction was delivered to a depth of 1 cm (Figure
2). Three fractions were delivered over 24 hours, spaced
at least six hours apart, beginning seven days after surgery.
The catheters were removed without complication
following completion of brachytherapy. External beam
irradiation to a total dose of 4500 cGy in 25 fractions was
begun four weeks after surgery. A simple treatment plan
utilised 6 MV photon beams of field size 6.4 cm x 16.3 cm.
Treatment was delivered without incident, and there were
no wound healing complications or evidence of
neurological injury.
Implantation technique & treatment planning
The surgeon outlines the tumour bed with several clips at
the time of resection. The radiation oncologist, who is
on standby, is summoned to the operating theatre and
confers with the surgeon. He/she then places parallel
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afterloading catheters across the tumour bed,
approximately 10 mm apart. The catheters are arrayed
perpendicular to the axis of the limb; each entering and
exiting through a separate skin puncture. The most
proximal and most distal catheters are placed to bracket
the tumour bed by 2 cm. The catheters are stiffened by
a wire or plastic filament, to prevent kinking. Securing
buttons are tightened after wound closure. Closing the
wound with a musculocutaneous flap reduces concern
that dwell locations will be too close to the dermis.
The limb undergoes CT scanning within three days
of the implant. Wires or dummy ribbons facilitate catheter
definition on the scan. The outermost dwell positions on
each catheter are placed 1.5-2.0 cm beyond the tumour
bed. No dwell position is placed within 1 cm of a skin
entry point.
The physicist designs a plan with the intent of
achieving a homogeneous dose at 1 cm depth from the
implanted catheters, by geometrical optimisation and
manual manipulation of the dwell times. This is achieved
by the following adjustments of relative dwell times [1].
Dwell times are more heavily weighted at each catheter
end [2]. All dwell times in the most proximal and distal
catheters are more heavily weighted [3]. Weighting of
dwell times is adjusted to compensate for regions of
suboptimal catheter spacing.
The physicist confirms that the prescription isodose
surface forms a slab of roughly 2 cm thickness by
converting the cursor to a circle of 2 cm diameter, and
placing the circle between the prescription isodose lines.
A simple calculation defines a standard treatment
volume (STV). The transverse dimensions of the im-
planted area (average length of the dwell position train in
each catheter, multiplied by the average distance between
the most proximal and distant catheters) is multiplied by
a standard thickness: 2 cm.
A dose-volume histogram (DVH) for the whole dose
matrix is calculated, and the plan is normalized, by
Figure 1a
Figure 1b
Figure 1. Example of the intraoperative portion of the treatment. 1a. Catheters were placed across the
tumour bed. Note that they were applied directly over the exposed nerve. 1b. A flap, harvested from the
forearm, was used to close the surgical wound. The site of the flap’s origin was repaired by a split-
thickness graft. (Note. The case depicted in Figure 1 is not the patient described in the text or Figure 2,
but rather a similar case utilised to depict the procedure.)
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adjusting the actual dwell times, so that the dose delivered
to a volume equivalent to the STV equals the prescription
dose.
Brachytherapy begins 4-6 days after surgery. Analysis
of our experience indicates that 13.5 Gy in three equal
fractions or 15.0 Gy in four equal fractions, are safe and
effective regimens when brachytherapy is combined with
45–50 Gy external beam therapy [1].
Discussion
Current imaging capabilities are invaluable in defining
a three-dimensional target volume when tumour can be
visualised. However, post-resection therapy poses the
challenge of defining a target volume, and consequently
a delivered dose, when the target itself is nebulous. A
prescription point, such as ‘to a depth of 10 mm’ is often
used as a surrogate target volume. Nevertheless, the locus
in the tumour bed from which the specified depth is to be
measured is subjective. As rapid dose fall-off is the
hallmark of brachytherapy and the isodose surface of an
implant is undulating, small variations in ‘point’ selection
may result in large differences in dose delivery.
The Paris system, devised to prescribe radiation in
the face of new technology (small afterloaded sources
such as 192Ir) has a built-in method of defining target
volume. This is based upon the placement and spacing of
the catheters. However, the Paris system’s rules specify
that linear activity should be uniform among and along
source lines [2]. This constraint negates the wonderful
flexibility of HDR to manipulate dwell times.
Lowell Anderson recognised this problem decades
ago. “If accurate registration of the dose distribution is
available with respect to 3D images, it may be possible to
determine the target region’s minimal peripheral dose,
which is generally accepted as the dose of greatest clinical
significance. In many instances, however, 3D images of
the region ... fail to show clearly the target outline”.
Anderson proposed a solution, the matched peripheral
dose. First, he relied on the surgeon to correctly define the
tumour bed intraoperatively, and the brachytherapist’s
appropriate placement of afterloading catheters to
adequately bracket the tumour bed. Then, “the matched
peripheral dose is defined as the dose for which the
contour volume is equal to the volume of an ellipsoid
having the same dimensions as the measured, mutually
perpendicular dimensions of the target region … In such
situations, the matched peripheral dose can serve as
a useful approximation to the minimum peripheral dose”
[3].
We resurrected Anderson’s concept to use with the
DVHs generated by modern dosimetry programs. First,
we agreed that the tumour bed was best defined by the
surgeon at time of resection, and delineated by the
placement of clips along the bed’s borders. The
brachytherapist then determines the target volume by the
intraoperative positioning of afterloading catheters. The
physicist or dosimetrist then manipulates dwell times and
Figure 2. HDR planning. The fractional dose (450 cGy) was prescribed to a target of 2 cm thickness (the red
isodose line) which was defined by the surgeon’s clips and by the brachytherapist’s catheter placement.
weighting of peripheral dwell positions more heavily, to
generate a homogenous dose distribution. Manipulation
of weighting is also used to partially compensate for
uneven catheter spacing.
A standard thickness of 2 cm (1 cm deep on either
side) is specified for all our planar implants. By
multiplying the average width by the average length of
the dwell positions, the area of the implant is calculated in
the plane of the catheters. The STV is defined by
multiplying this area by a standard target thickness which,
in our institution is taken to be 2 cm. We then adjust
dwell times so that the prescribed dose is delivered to
a volume equivalent to the STV.
Purists would argue that this technique delivers dose
to an artificially created volume that may have no bearing
to the true tumour volume. However, if the surgeon,
brachytherapist, and dosimetrist have performed well, an
ellipsoid isodose will be delivered to the best possible
estimation of the target.
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